

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
08/935,377	09/22/1997	MAURICE ZAUDERER	PENY4-628885	8588
7590 12/04/2001 STERNE, KESSLER, GOLDSTEIN & FOX P. LLC SUITE 600 1100 NEW YORK AVENUE N.W.			EXAMINER	
			DECLOUX, AMY M	
WASHINGTON, DC 200053934			ART UNIT	PAPER NUMBER
			1644	z9

DATE MAILED: 12/04/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 08/935,377

Applicant(s)

Examiner

DeCloux, Amy

Art Unit

1644

Zauderer



	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Th MAILING DATE of this communication appear	s on th cov r sheet with the correspondenc address
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SETHE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rebe considered timely. - If NO period for reply is specified above, the maximum statutory periodommunication. - Failure to reply within the set or extended period for reply will, by statue. - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b). Status 1) X Responsive to communication(s) filed on Mar 17.	And the statutory minimum of thirty (30) days will dwill apply and will expire SIX (6) MONTHS from the mailing date of this ste, cause the application to become ABANDONED (35 U.S.C. § 133). ling date of this communication, even if timely filed, may reduce any
2a) ☐ This action is FINAL . 2b) ☒ This action is in condition for allowance closed in accordance with the practice under Ex	except for formal matters, prosecution as to the merits is parte Quayl@35 C.D. 11; 453 O.G. 213.
Disposition of Claims	is/are pending in the applica
4a) Of the above, claim(s)	is/are withdrawn from considera
5) Claim(s)	is/are anowed.
C\ Claim(c)	197410 10,0000
7) [Olairo (a)	
8) 🗓 Claims <u>68-120</u>	are subject to restriction and/or election requiren
Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on	is: a∬ approved b)⊡disapproved.
Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign a) All b) Some* c) None of: 1. Certified copies of the priority documents have a copies of the priority documents have application from the International Bur *See the attached detailed Office action for a list of the priority application from the International Bur Acknowledgement is made of a claim for domestication.	ave been received. ave been received in Application No documents have been received in this National Stage eau (PCT Rule 17.2(a)). the certified copies not received.
Attachment(s)	(DTO 440) Deace Notes
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	

DETAILED ACTION

Note: The examiner of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Amy DeCloux, Group Art Unit 1644, Group 1640, Technology Center 1600.

- 1. Applicant's election with traverse in paper No. 28, filed 9-19-2001 is acknowledged. However in view of the new restriction imposed as detailed below, applicant's traversal is rendered moot.
- 2. This application contains inventions drawn to patentably distinct species. Applicant is required under 35 USC 121 to elect a specific method of selecting a nucleic acid molecule encoding a target epitope comprising:
- A) a specific source of heterologous nucleic acid such as tumor cells as recited in claim 92,
- B) host cells that express a specific MHC molecule, such as MHC Class I as recited in claim 118 or 120,
 - C) a vector of specific origin, such as vaccinia, as recited in claim 77,
 - D) a specific transfer plasmid such as one recited in claim 116,
 - E) a specific helper virus, such as one recited in claim 105 or claim 106.
- 3. These species are distinct because each of the heterologous nucleic acids, MHC Class I and II molecules, vectors, transfer plasmids and helper viruses are physically and structurally distinct, and therefore represent distinct ingredients in the claimed method. Therefore, the species are patentably distinct species in view of each other. Applicant is required to elect a single disclosed species, even though this requirement is traversed.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claim 58 is generic.

4. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration

of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy DeCloux whose telephone number is (703) 306-5821. The examiner can normally be reached Monday through Friday from 9:00 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Amy DeCloux, Ph.D.
Patent Examiner
Group 1644
Technology Center 1600
November 30, 2001

David Chaunders

PRIMARY EXAMINER

ART UNIT: 182/644